Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Death attributed to methadone.

S V Vormfelde1, W Poser

  • 1Department of Clinical Pharmacology, University Hospital, Göttingen. stefan.vormfelde@med.uni-goettingen.de

Pharmacopsychiatry
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The genetics of loop diuretic effects.

The pharmacogenomics journal·2010
Same author

The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin.

Clinical pharmacology and therapeutics·2009
Same author

Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.

Clinical pharmacology and therapeutics·2009
Same author

Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.

Clinical pharmacology and therapeutics·2008
Same author

The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele *3 independently affect torsemide pharmacokinetics and pharmacodynamics.

Clinical pharmacology and therapeutics·2007
Same author

Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs.

Clinical pharmacology and therapeutics·2007
Same journal

Correction: Escitalopram and Clonazepam Affect Gasotransmitter-related Enzyme (nNOS, HO-2, CBS) Gene Expression in the Rat Brain.

Pharmacopsychiatry·2026
Same journal

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same journal

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same journal

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
Same journal

A Naturalistic Study on the Cost Reduction and Efficacy of Long-acting Antipsychotics in an Early Intervention Programme for Patients with Recent-onset Psychosis.

Pharmacopsychiatry·2026
Same journal

High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting.

Pharmacopsychiatry·2026
See all related articles

Methadone maintenance treatment (MMT) significantly reduces mortality in heroin addicts. However, deaths attributed to methadone, often from abuse of take-home doses or during initial treatment, can be prevented through policy changes and improved patient management.

Area of Science:

  • Addiction Medicine
  • Pharmacology
  • Public Health

Background:

  • Methadone maintenance treatment (MMT) is crucial for reducing mortality among intravenous heroin users.
  • Despite MMT's benefits, deaths attributed to methadone, both in patients and non-patients, remain a concern.

Purpose of the Study:

  • To identify the primary causes of methadone-related deaths.
  • To propose strategies for preventing these fatalities and enhancing MMT's overall benefit and public acceptance.

Main Methods:

  • Analysis of circumstances surrounding deaths attributed to methadone.
  • Review of existing MMT protocols and potential risk factors.
  • Evaluation of alternative medications and harm reduction strategies.

Related Experiment Videos

Main Results:

  • 69% of methadone-related deaths occurred in individuals not currently on MMT, primarily due to diverted take-home methadone abuse.
  • 51% of deaths among MMT patients happened during the dose-finding phase.
  • Other risk factors include concurrent methadone use, post-prison discharge, and intravenous methadone injection.

Conclusions:

  • Restricting take-home methadone prescriptions, especially to longer-acting or safer alternatives like LAAM or buprenorphine, could significantly reduce deaths.
  • Careful patient monitoring during dose titration, pre-discharge planning for incarcerated individuals, and adjunct naloxone for high-risk injections are vital prevention strategies.
  • Reducing methadone-related deaths improves MMT's net benefit and public perception.